An Open-Label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients with Relapsed and/or Refractory Follicular Lymphoma
Study Status
Open to Enrollment
Study Description
This clinical trial is for men and women with follicular lymphoma who have either relapsed after taking standard treatments or did not respond to (refractory to) standard treatments. The study is evaluating an experimental drug called MLN9708. The purpose of the study is to determine the effectiveness of MLN9708 in treating relapsed/refractory follicular lymphoma.
Disease Status and/or Stage
Relapsed or refractory follicular lymphoma
Sponsor
Millennium Pharmaceuticals
Key Eligibility
- Men and women age 18 and older
- Diagnosed with follicular lymphoma
- Relapsed and/or refractory after at least 1 prior therapy
- Detailed eligibility reviewed when you contact the study team
- Rita Gazivoda
- (212) 746-0702
- [email protected]
Principal Investigator
Contact
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]